Posted by Michael Wonder on 03 Feb 2019
Erenumab in migraine: indication of a significant added benefit for certain patients
2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted.
Erenumab came to the German market in November 2018 as the first of a new class of drugs for the prophylaxis of migraine. In an early benefit assessment, the IQWiG is now investigating whether erenumab offers added clinical value. As shown by the data provided by the manufacturer, erenumab can reduce the burden of migraine for patients in whom the use of other drugs for prophylaxis has failed or is not appropriate.
The manufacturer provided data only for episodic migraine, but not for chronic migraine. However, since this classification is based solely on the number of days of pain and the boundaries between episodic and chronic migraine are blurred, the IQWiG does not consider the indication of significant added benefit to be limited to episodic migraine.
